
Opinion|Videos|March 13, 2025
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Author(s)Matthew Galsky, MD
An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as nonurothelial tract recurrence-free survival (NUTRFS), distant metastasis-free survival (DMFS), and second progression-free survival (PFS2). An exploratory analysis assessed outcomes in the muscle-invasive urothelial carcinoma (MIBC) subgroup, prior neoadjuvant chemotherapy (NAC) use, and PD-L1 expression. This analysis was conducted to further evaluate efficacy across subgroups and refine the understanding of treatment impact.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please review the updated results from CheckMate 274. (Galsky 2025)
- Updated DFS and interim OS
- Other end points (eg, NUTRFS, DMFS, PFS2)
- Exploratory analysis of MIBC subgroup, prior NAC, PD-L1 expression
- Why was this analysis performed?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















